Stock listing

Royalty Pharma Plc

Selected listing: A2P62D · LS · EUR · DE

Royalty Pharma Plc (Lang & Schwarz: A2P62D), Health Technology. Latest release Sep 15, 2026: Royalty Pharma announces $7.5 million gift to Blood Cancer United…

A2P62D:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2P62D
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

About Royalty Pharma Plc

Royalty Pharma Plc (ticker: RPRX) is a public company based in the United States, specializing in acquiring and managing revenue-generating pharmaceutical royalties. Royalty Pharma aims to create value through its diverse portfolio of royalty interests in innovative therapies.

Latest news from Royalty Pharma Plc

Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program

September 15, 2026

Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen

September 4, 2026

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

August 12, 2026

Royalty Pharma reports second quarter 2026 results

August 5, 2026

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

August 3, 2026

All Royalty Pharma Plc news →

Events

Replays

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call
Wed, Aug 05, 2026 · 08:00 AM ET
Watch
Royalty Pharma plc (RPRX) Q1 2026 Earnings Call
Wed, May 06, 2026 · 08:00 AM ET
Watch
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call
Wed, Feb 11, 2026 · 08:00 AM ET
Watch

Research Royalty Pharma Plc

Royalty Pharma Plc company profile

View the public company page for Royalty Pharma Plc on 6ix.

Royalty Pharma Plc news

Read company news and market updates connected to Royalty Pharma Plc.

Royalty Pharma Plc investor events

Find investor webinars, events, and replay context for Royalty Pharma Plc.